MAZE
Maze Therapeutics, Inc.
36.73
+1.28 (+3.61%)
52w low 21.95
53.65 high
46.6% of range
Financial Analysis
| (USD) | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | -- | 264.54M | 316.77M | 189.25M | 198.77M | 202.64M | |
| Receivables | -- | -- | -- | -- | 20.00M | -- | |
| Current Assets | -- | 271.15M | 391.30M | 349.72M | 379.78M | 420.42M | |
| Net PP&E | -- | 27.71M | 26.46M | 25.16M | 23.97M | 22.83M | |
| Total Assets | -- | 303.52M | 422.06M | 397.13M | 419.71M | 531.62M | |
| Current Liabilities | -- | 19.90M | 22.11M | 22.56M | 21.24M | 22.96M | |
| Total Debt | -- | 25.01M | 24.18M | 23.31M | 61.22M | 60.42M | |
| Total Liabilities | -- | 41.28M | 42.62M | 42.16M | 78.01M | 78.50M | |
| Retained Earnings | -- | -424.89M | -454.98M | -489.55M | -513.75M | -558.48M | |
| Shareholders Equity | -- | 262.24M | 379.44M | 354.97M | 341.70M | 453.12M | |
| Working Capital | -- | 251.25M | 369.19M | 327.16M | 358.54M | 397.46M | |
| Shares Outstanding | -- | 43.85M | 48.08M | 49.34M | 49.74M | 55.50M |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
-100.0%